4.4 Review

New plays in the p53 theater

Journal

CURRENT OPINION IN GENETICS & DEVELOPMENT
Volume 21, Issue 1, Pages 86-92

Publisher

CURRENT BIOLOGY LTD
DOI: 10.1016/j.gde.2010.10.002

Keywords

-

Funding

  1. National Cancer Institute [R37 CA40099]
  2. Flight Attendant Medical Research Institute
  3. European Commission [201102, 223151]
  4. Robert Bosch Foundation
  5. M.D. Moross Cancer Institute

Ask authors/readers for more resources

The p53 tumor suppressor and its paralogs p63 and p73 are at the crux of a network modulating cellular responses against potentially tumorigenic events. p53 acts primarily as a transcription factor, regulating the expression of both coding and non-coding RNAs, as well as the activity of RNA processing complexes. In line with their anti-tumorigenic function, p53 and p63 have recently been implicated in restricting tumor cell invasion. In parallel, a growing number of non-canonical target genes have been added to the p53 repertoire. These include genes encoding for proteins that impinge on a broad spectrum of cellular functions, from cell metabolism to stem cell renewal. The p53 story is still far from being fully told.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available